NEW YORK, July 6, 2015 /PRNewswire/ -- Attorney Advertising
-- Bronstein, Gewirtz & Grossman, LLC reminds investors that a
securities class action has been filed in the United States
District Court for the Southern District of California on behalf of those who purchased
shares of Celladon Corporation ("Celladon" or the "Company")
(NasdaqGM: CLDN), during the period between July 7, 2014 and June 25,
2015 inclusive. (the "Class Period").
The Lawsuit alleges that during the Class Period, Defendants
made false and misleading statements regarding and/or failed to
disclose adverse information regarding the prospects for
MYDICAR. Specifically the complaint alleges that: (i) success
in the CUPID1 trial was not indicative of any success in the CUPID2
trial since the CUPID1 trial was extremely small; and (ii) the
Company's existence was tied to the trial results and defendants
were aware of their limitations.
On April 26, 2015, the Company
announced that "its Phase 2b CUPID2 trial did not meet its primary
and secondary endpoints. CUPID2 is a randomized, double-blind,
placebo-controlled, multinational trial evaluating a single,
one-time, intracoronary infusion of the cardiovascular gene therapy
agent MYDICAR(R) (AAV1/SERCA2a) versus placebo added to a maximal,
optimized heart failure drug and device regimen."
Following this news, shares of Celladon fell $10.78 or 78.80%, during intraday trading to
trade at $2.90 on April 27, 2015.
Then on June 26, 2015, Celladon
announced the suspension of research and development of its MYDICAR
program and the possible liquidation of the company.
Following this news, Celladon stock fell $0.85 or 38% to close at $1.35 per share.
No Class has yet been certified in the above action. If you wish
to review a copy of the Complaint, to discuss this action, or have
any questions, please contact Peretz
Bronstein, Esq. or his Investor Relations Coordinator
Eitan Kimelman of Bronstein, Gewirtz
& Grossman, LLC at 212-697-6484 or via email info@bgandg.com.
Those who inquire by e-mail are encouraged to include their mailing
address and telephone number. If you suffered a loss in
Celladon you have until August 31,
2015 to request that the Court appoint you as lead
plaintiff. Your ability to share in any recovery doesn't
require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation
boutique. Our primary expertise is the aggressive pursuit of
litigation claims on behalf of our clients. In addition to
representing institutions and other investor plaintiffs in class
action security litigation, the firm's expertise includes general
corporate and commercial litigation, as well as securities
arbitration. Attorney advertising. Prior results do not
guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
info@bgandg.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-reminds-investors-of-class-action-against-celladon-corporation-and-lead-plaintiff-deadline-300108883.html
SOURCE Bronstein, Gewirtz & Grossman, LLC